Antigenics cancer vaccine study shows mixed results

Feb 20 (Reuters) - Antigenics Inc (AGEN.O) said a late-stage trial of its cancer vaccine, Oncophage, in the treatment of metastatic melanoma, a serious form of skin cancer, did not meet its primary goal of overall survival.

The biotechnology company said patients in the Oncophage arm fared similarly to those in the physician's choice arm in terms of overall survival.

However, the study showed that patients receiving at least 10 injections of Oncophage had improved median survival of about 3.7 months, the company added. (Reporting by Jennifer Robin Raj in Bangalore; Editing by Deepak Kannan)